Case Study

US commercialization strategy for target asset

US commercialization strategy for target asset
Cello Health Consulting
OPPORTUNITY ASSESSMENTS, FORECASTING AND VALUATION

THE CLIENT

A Chinese Biotech, with an internal drug discovery platform, looking to expand their portfolio within China and the US. The company has an interest in investment and licensing opportunities in China (and potentially globally) to further establish their footprint as a global player in oncology

THE BUSINESS CHALLENGE

The client wanted to in-license a novel MOA asset that could target certain virally-induced cancers. They sought help with performing due diligence on the asset with regards to the US market opportunity

OUR APPROACH

We performed an independent assessment of multiple potential indications for the novel MOA asset via primary and secondary research


THE RESULTS

Our assessment and recommendations informed indication selection and sequencing for the novel MOA asset that would minimize risk and optimize market potential. In addition, we identified potential clinical development strategies in the US that could synergize with the client’s development in China. We provided an outlined context of development in China vs. US, providing strong guidance for a deal sheet & Business Development strategy

First deliverables for a US opportunity assessment

Read case study
Case Study

Portfolio strategy and opportunity assessment to support decisions and clinical development

Read case study
Case Study

Navigating First Product Commercialization

Read case study
Case Study

Let's work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us